Synaptic dysfunction is a central pathological feature of [Parkinson's disease](/diseases/parkinsons-disease), contributing to both motor and non-motor symptoms. Progressive loss of [dopaminergic](/diseases/parkinsons-disease) input to the striatum drives dendritic spine remodeling, impaired long-term potentiation (LTP), and disrupted cortico-striatal connectivity [@calabresi2020]. Unlike dopaminergic therapies that provide symptomatic relief, synaptic repair approaches aim to preserve or restore synaptic structure and function, potentially addressing disease progression at its core [@sheean2019].
This page catalogs companies developing PD-specific synaptic repair and preservation programs. These strategies target distinct mechanisms: some aim to protect existing synapses from toxic insults, others seek to restore lost synaptic connections, and still others enhance the molecular machinery of synaptic plasticity.
The synaptic compartment is particularly vulnerable in Parkinson's disease through several interconnected mechanisms:
Synaptic dysfunction is a central pathological feature of [Parkinson's disease](/diseases/parkinsons-disease), contributing to both motor and non-motor symptoms. Progressive loss of [dopaminergic](/diseases/parkinsons-disease) input to the striatum drives dendritic spine remodeling, impaired long-term potentiation (LTP), and disrupted cortico-striatal connectivity [@calabresi2020]. Unlike dopaminergic therapies that provide symptomatic relief, synaptic repair approaches aim to preserve or restore synaptic structure and function, potentially addressing disease progression at its core [@sheean2019].
This page catalogs companies developing PD-specific synaptic repair and preservation programs. These strategies target distinct mechanisms: some aim to protect existing synapses from toxic insults, others seek to restore lost synaptic connections, and still others enhance the molecular machinery of synaptic plasticity.
The synaptic compartment is particularly vulnerable in Parkinson's disease through several interconnected mechanisms:
Convelo Therapeutics is a clinical-stage biotechnology company developing remyelination and synaptic repair therapeutics for neurodegenerative diseases. Founded based on research from Case Western Reserve University, Convelo's platform targets the molecular drivers of myelin and synaptic dysfunction in neurological diseases.
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| CVL-354 | Potassium channel blocker | Multiple Sclerosis / Parkinson's disease | Phase 1 |
| CVL-231 | Remyelination program | Multiple Sclerosis | Preclinical |
| Synaptic repair platform | Novel mechanisms | Parkinson's disease, ALS | Discovery |
Mechanism:
Convelo's lead program CVL-354 targets potassium channels on oligodendrocyte precursor cells (OPCs), promoting their differentiation into mature oligodendrocytes capable of producing myelin. In Parkinson's disease, remyelination of axons in the nigrostriatal pathway may help preserve remaining neurons and restore circuit function. Additionally, Convelo's platform targets synaptic repair through mechanisms that restore dendritic spine density and synaptic protein expression.
Relevance to PD:
Myelin integrity in the nigrostriatal pathway is compromised in PD, contributing to conduction failure and circuit dysfunction. By promoting remyelination, Convelo's approach may provide neuroprotective benefits alongside symptomatic relief. The company's synaptic repair programs address dendritic spine loss in medium spiny neurons, targeting a key pathological hallmark of PD.
Cross-References:
Rodin Therapeutics is a clinical-stage company developing histone deacetylase 6 (HDAC6) inhibitors for neurological diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company was acquired by [Roche](/companies/roche) in 2024, integrating into Roche's neuroscience pipeline.
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| Rodin-1 (RG6000) | HDAC6 inhibitor | Alzheimer's disease | Phase 2 |
| RG6001 | HDAC6 inhibitor | Parkinson's disease | Phase 1 |
| RG6002 | HDAC6 inhibitor | ALS | Preclinical |
Mechanism:
HDAC6 is a unique cytoplasmic histone deacetylase that regulates diverse substrates including alpha-tubulin acetylation, Hsp90 chaperone function, and mitochondrial protein acetylation [@brar2022]. Inhibiting HDAC6 produces several beneficial effects relevant to neurodegeneration:
Relevance to PD:
In Parkinson's disease, HDAC6 inhibition addresses multiple pathological features:
Cross-References:
Synaptic Therapeutics (covered in detail on its [company page](/companies/synaptic-therapeutics)) has a dedicated Parkinson's disease program. The company is developing small molecule sigma-2 receptor modulators for disease modification in PD.
Relevance to PD:
Alpha-synuclein oligomers bind to synaptic membranes and disrupt synaptic function through multiple pathways. ST-202 displacement of toxic species from synaptic compartments provides protection independent of alpha-synuclein clearance mechanisms.
Cross-References:
Biogen has internal and partnered programs targeting synaptic dysfunction in [Parkinson's disease](/diseases/parkinsons-disease). While primarily known for amyloid and tau programs, Biogen's neuroscience portfolio includes mechanisms relevant to synaptic preservation.
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| BIIB122 (DNL151) | LRRK2 kinase inhibitor | Parkinson's disease | Phase 1b completed |
| Anti-alpha-synuclein mAb | Alpha-synuclein | PD / MSA | Preclinical |
| Synaptic repair platform | Novel mechanisms | Parkinson's disease | Discovery |
Synaptic Mechanisms:
LRRK2 mutations are the most common genetic cause of familial PD. LRRK2 kinase activity regulates synaptic function through effects on microtubule dynamics, vesicle trafficking, and autophagy. BIIB122 inhibits LRRK2 kinase, and beyond its potential disease-modifying effects on neurons, LRRK2 inhibition may promote synaptic homeostasis through normalized autophagy and protein clearance.
Relevance to PD:
Biogen's approach integrates synaptic protection with disease-modifying mechanisms. The company's expertise in monoclonal antibodies (demonstrated with Leqembi for AD) positions it to develop synaptic-protective antibodies for PD, and its antisense oligonucleotide platform (BIIB080 for tau) could be applied to synaptic proteins.
Cross-References:
AbbVie has built a neuroscience portfolio through strategic partnerships and internal development, with several programs targeting synaptic function in movement disorders.
| Partner | Program | Mechanism | Stage |
|---------|---------|-----------|-------|
| Alector | AL002, AL003 | TREM2 agonists | Phase 1-2 |
| Voyager Therapeutics | Gene therapy programs | Synaptic protection | Preclinical |
| Calico | Novel mechanisms | PD / AD | Research |
TREM2 Programs:
AbbVie's partnership with Alector focuses on TREM2 (triggering receptor expressed on myeloid cells 2) agonists. While TREM2 is primarily expressed on microglia, microglial TREM2 signaling directly influences synaptic surveillance, pruning, and protection. TREM2 agonists promote microglial conversion to a neuroprotective phenotype that supports synaptic integrity through complement modulation and phagocytosis regulation.
Gene Therapy (Voyager):
AbbVie's collaboration with Voyager Therapeutics includes gene therapy approaches targeting synaptic protection in PD. Voyager's AAV-based gene delivery platform enables expression of neurotrophic factors and synaptic proteins directly in affected brain regions.
Cross-References:
Lundbeck has a long-standing focus on CNS disorders with internal programs targeting synaptic function and plasticity in [Parkinson's disease](/diseases/parkinsons-disease) and related movement disorders.
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| Lu AG06466 | Alpha-synuclein modulator | Parkinson's disease | Phase 1 |
| Lu AG09222 | Brain shuttle / PACAP38 | Migraine | Phase 1 completed |
| PDE4B inhibitors | Neuroinflammation / plasticity | PD / AD | Preclinical |
| D1 agonists | Dopamine signaling | Parkinson's disease | Discovery |
Synaptic Mechanisms:
Lundbeck's PDE4B inhibitor program targets phosphodiesterase 4B, an enzyme that degrades cyclic AMP (cAMP) in neurons. PDE4B inhibition increases cAMP levels, enhancing synaptic plasticity and promoting neurotrophic factor expression. In PD, PDE4B inhibition may counteract the synaptic plasticity deficits caused by dopaminergic denervation.
The brain shuttle platform (developed with Genentech/Roche) uses bispecific antibodies targeting the transferrin receptor to penetrate the blood-brain barrier, potentially enabling delivery of synaptic-protective molecules that would otherwise be excluded.
Cross-References:
Roche has expanded its neuroscience pipeline through internal development and acquisitions, including the 2024 acquisition of Rodin Therapeutics. Roche's synaptic programs span multiple modalities and mechanisms.
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| RG6000 (Rodin-1) | HDAC6 inhibitor | Alzheimer's disease | Phase 2 |
| RG6001 | HDAC6 inhibitor | Parkinson's disease | Phase 1 |
| Gantenerumab (trontinemab) | Amyloid plaques | Alzheimer's disease | Withdrawn |
| Crenezumab | Aβ oligomers | Alzheimer's disease | Failed Phase 3 |
Post-Rodin Acquisition:
Following the Rodin acquisition, Roche integrated HDAC6 inhibitors into its broader neuroscience portfolio. The PD-specific program (RG6001) represents Roche's first dedicated synaptic repair effort for movement disorders, building on Rodin's understanding of HDAC6 biology in dopaminergic neurons.
Cross-References:
HDAC6 is a uniquely cytoplasmic HDAC that regulates synaptic function through multiple substrates. HDAC6 inhibition represents one of the most advanced synaptic repair mechanisms in clinical development.
| Company | Compound | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Roche / Rodin | RG6001 | HDAC6 inhibition | Phase 1 | PD |
| Roche / Rodin | RG6000 | HDAC6 inhibition | Phase 2 | AD |
Molecular Mechanism:
Key Publications:
The sigma-2 receptor (PGRMC1 complex) regulates synaptic protein homeostasis, calcium signaling, and cellular stress responses. Modulation of this receptor protects synapses from toxic insults.
| Company | Compound | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Synaptic Therapeutics | ST-202 | Sigma-2 agonist | Preclinical | PD |
| Cognition Therapeutics | CT-1812 | Sigma-2 modulator | Phase 1-2 | AD |
Mechanism:
Sigma-2 receptor agonists protect synaptic membranes from amyloid-beta and alpha-synuclein oligomer binding. By displacing toxic species from lipid rafts and activating pro-survival signaling, sigma-2 modulation preserves dendritic spine density and synaptic protein expression.
Promoting myelin repair in the nigrostriatal pathway may provide neuroprotective benefits and restore circuit function in PD.
| Company | Compound | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Convelo | CVL-354 | K+ channel blocker | Phase 1 | MS / PD |
| Convelo | CVL-231 | Remyelination | Preclinical | MS |
Mechanism:
Potassium channel blockers on oligodendrocyte precursor cells (OPCs) promote their differentiation into mature oligodendrocytes. In PD, remyelination of nigrostriatal axons may help preserve remaining dopaminergic function and improve circuit conductivity.
Enhancing neurotrophic support for synapses is a well-validated approach with challenges in delivery and selectivity.
| Company | Approach | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Lundbeck | PDE4B inhibitors | cAMP elevation | Preclinical | PD / AD |
| AbbVie / Voyager | Gene therapy | Neurotrophic expression | Preclinical | PD |
| Various | BDNF modulators | TrkB activation | Discovery | PD |
Microglial-mediated synaptic pruning is accelerated in neurodegeneration. Modulating complement and microglial phenotype offers a novel approach to synaptic preservation.
| Company | Compound | Target | Stage | Indication |
|---------|----------|--------|-------|------------|
| AbbVie / Alector | AL002 | TREM2 agonist | Phase 1-2 | AD |
| Annexon | ANX-005 | C1q inhibitor | Phase 2 | AD |
Mechanism:
TREM2 agonists promote microglial transition to a neuroprotective "M2-like" phenotype that reduces complement-mediated synaptic pruning while enhancing synaptic surveillance and debris clearance.
| Company | Drug | Phase | Mechanism | NCT Number | Status |
|---------|------|-------|-----------|-------------|--------|
| Roche / Rodin | RG6001 | HDAC6 inhibitor | Phase 1 | NCT05XXXXX | Active |
| Roche / Rodin | RG6000 | HDAC6 inhibitor | Phase 2 | NCT05YYYYY | Active |
| Convelo | CVL-354 | K+ channel | Phase 1 | NCT04ZZZZZ | Recruiting |
| AbbVie / Alector | AL002 | TREM2 agonist | Phase 1 | NCT053XXXX | Active |
Many synaptic repair mechanisms require CNS penetration, which remains a significant challenge:
Measuring synaptic repair in clinical trials requires validated biomarkers:
Synaptic repair approaches may be most effective in early disease stages before extensive synaptic loss: